What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment
Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Amgen Obesity Drug Cut Weight In Closely Watched Study
A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...
Amgen's obesity drug cuts weight by up to 20%, trial data drags down shares
Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% weight on average in a year-long ...
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
BioPharma Dive1d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
FierceBiotech1d
Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Amgen stock slips as obesity drug study disappoints Wall Street
Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly ...
AMGN Stock Down Despite Strong Data From Obesity Drug Study
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
STAT1d
Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...